Topas Therapeutics GmbH

Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance

Topas Therapeutics GmbH: Paul Sekhri joins Topas Therapeutics as Chairman of the Board